Session Title: Free Paper Session 22: AMD V
Session Date/Time: Sunday 10/09/2017 | 08:00-09:30
Paper Time: 09:12
Venue: Room 115
First Author: : N.Padrón Pérez SPAIN
Co Author(s): : L. Arias M. Rubio D. Lorenzo P. Garcia-Bru J. Catala Mora J. Caminal
To evaluate changes in choroidal thickness after intravitreal injection (IVI) therapy for pachychoroid neovasculopathy (PNV).
Observational, retrospective, consecutive case series.
The study sample consisted of 18 patients (18 eyes) who underwent anti-vascular endothelial growth factor (anti-VEGF) therapy for PNV. The 18 fellow eyes in these patients were used as a control group. All eyes were evaluated with swept-source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCT-A).
Mean patient age was 68.3±7.0 years. Mean follow up was 16.4±2.0 months. No differences in the best-corrected visual acuity (BCVA) of the affected eyes were observed between baseline and 12-month follow up (median ETDRS, 77.5 vs. 76 letters, P=.074; median LogMAR, 0.22 vs. 0.22, P=.453). However, subfoveal choroidal thickness (SFCT) decreased significantly, from a mean of 317.7±39.9 µm at baseline to 266.9±56.3 µm at 12 months (P≤.001). The median change in SFCT at 12 months was 44.0 µm (range, 17-133 µm). SFCT decreased by 16% from baseline to month 12. The change in SFCT at 12 months was highly correlated with the number of IVI (rs=0.762, P≤.001). No significant changes in SFCT were observed in the fellow eyes over the 12-month study period (median, 267.5 µm vs. 267.0 µm; P=.930).
The present study reveals a significant reduction in choroidal thickness after 12 months of anti-VEGF intravitreal injections in eyes with PNV. Since PNV is part of the pachychoroid clinical spectrum, the decreased choroidal thickness in our patients might be attributable to a reduction in choroidal vascular permeability. The total number of intravitreal injections was highly correlated with the decrease in choroidal thickness.